ABIVAX confirms trading resumption

Paris, May 2nd, 2017 at 7:00am CEST – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, confirms the resumption of trading effective as of Euronext Paris market opening at 9:00am CEST.

As a reminder, trading was suspended, as requested by the company and in agreement with the AMF (French Market Authority), on Friday April, 28th 2017 at 11:29am (CEST).

The company will also disclose top line results of ABX464-004, the 2nd Phase IIa of ABX464, its lead drug candidate in the treatment of HIV, today before market opening. 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41